For example, CDK 4/6 inhibitors combined with endocrine therapy are now standard first line treatment for metastatic hormone receptor positive, HER2 negative breast cancer based on significant improvements in progression free survival and overall survival [11,12,13]. Here, ERBB2 is linked to breast cancer.